X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with TTK HEALTHCARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs TTK HEALTHCARE - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH TTK HEALTHCARE PANACEA BIOTECH/
TTK HEALTHCARE
 
P/E (TTM) x 173.9 50.7 343.0% View Chart
P/BV x 3.9 9.3 41.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   TTK HEALTHCARE
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
TTK HEALTHCARE
Mar-14
PANACEA BIOTECH/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs149663 22.4%   
Low Rs82399 20.6%   
Sales per share (Unadj.) Rs84.1535.6 15.7%  
Earnings per share (Unadj.) Rs-18.315.9 -114.8%  
Cash flow per share (Unadj.) Rs-6.720.0 -33.5%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs83.7137.6 60.8%  
Shares outstanding (eoy) m61.257.77 788.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.41.0 138.4%   
Avg P/E ratio x-6.333.3 -18.9%  
P/CF ratio (eoy) x-17.226.5 -65.0%  
Price / Book Value ratio x1.43.9 35.7%  
Dividend payout %025.1 0.0%   
Avg Mkt Cap Rs m7,0744,127 171.4%   
No. of employees `0002.81.7 161.0%   
Total wages/salary Rs m1,449607 238.9%   
Avg. sales/employee Rs Th1,874.12,436.7 76.9%   
Avg. wages/employee Rs Th527.0355.2 148.4%   
Avg. net profit/employee Rs Th-407.772.5 -562.1%   
INCOME DATA
Net Sales Rs m5,1544,162 123.8%  
Other income Rs m10061 163.1%   
Total revenues Rs m5,2544,223 124.4%   
Gross profit Rs m-766197 -388.8%  
Depreciation Rs m71132 2,242.9%   
Interest Rs m1,50330 5,026.8%   
Profit before tax Rs m-2,881197 -1,464.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1773 23.1%   
Profit after tax Rs m-1,121124 -905.0%  
Gross profit margin %-14.94.7 -314.0%  
Effective tax rate %-0.637.0 -1.6%   
Net profit margin %-21.83.0 -730.8%  
BALANCE SHEET DATA
Current assets Rs m3,8101,629 233.9%   
Current liabilities Rs m8,3651,058 790.8%   
Net working cap to sales %-88.413.7 -644.3%  
Current ratio x0.51.5 29.6%  
Inventory Days Days15630 522.8%  
Debtors Days Days6734 200.2%  
Net fixed assets Rs m14,480556 2,602.9%   
Share capital Rs m6178 78.9%   
"Free" reserves Rs m903878 102.8%   
Net worth Rs m5,1271,069 479.5%   
Long term debt Rs m5,832159 3,674.7%   
Total assets Rs m19,4332,399 809.9%  
Interest coverage x-0.97.6 -12.1%   
Debt to equity ratio x1.10.1 766.4%  
Sales to assets ratio x0.31.7 15.3%   
Return on assets %2.06.4 30.6%  
Return on equity %-21.911.6 -188.7%  
Return on capital %3.618.5 19.7%  
Exports to sales %24.50.8 3,102.0%   
Imports to sales %10.21.4 726.9%   
Exports (fob) Rs m1,26433 3,841.3%   
Imports (cif) Rs m52558 900.2%   
Fx inflow Rs m1,53933 4,678.4%   
Fx outflow Rs m94263 1,490.7%   
Net fx Rs m597-30 -1,971.6%   
CASH FLOW
From Operations Rs m599127 473.3%  
From Investments Rs m-438-146 299.9%  
From Financial Activity Rs m-30322 -1,381.7%  
Net Cashflow Rs m-1413 -5,652.0%  

Share Holding

Indian Promoters % 74.5 65.4 113.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 3.7 16.2%  
FIIs % 1.3 5.2 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 25.8 91.5%  
Shareholders   10,259 12,723 80.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS